ADC Therapeutics S.A.

NYSE:ADCT

Biotechnology

Healthcare
$1.37 -1.35%

-$0.02 today

Market cap
$192.71M
Beta
1.77
P/E (TTM)
-1.2
EPS (TTM)
-$0.89
52W Low $0.78High $4.98

Volume 1.17M

Average 1.68M

ADCT Accounts Receivables

Cash effect of the change in amounts owed by customers; growing receivables consume cash.

ADC Therapeutics S.A.NYSE: ADCT

Accounts Receivables · Q1 FY2026 · quarter ended Mar 2026

Accounts receivables dips below year-ago levels

Q1 FY2026 accounts receivables of $1.93M (cash outflow) fell 83.2% year over year, behind the +106.0% change in trailing-twelve-month accounts receivables. Sequentially, it fell 69.9% from the prior quarter. Over 3 fiscal years it compounded at -41.0% a year.

Context

  • Accounts receivables amounted to 10.8% of revenue in FY2025, up 4.1 pp from a year earlier.
  • Accounts receivables increased in 1 of the last 3 fiscal years.

What to watch

Whether quarterly growth recovers from -83.2% toward the trailing-twelve-month pace of +106.0%.

Sources:Cash FlowText generated from reported figures; not investment advice.

Latest quarterMar 2026
-$1.93M-69.9% QoQ
Last fiscal yearDec 2025
-$8.79M-284.2% YoY
LTMMar 2026
$516.86K+106.0% YoY
Accounts Receivables past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter-83.2%——
1 year-284.2%——
3-year CAGR-41.0%——
5-year CAGR——
10-year CAGR——

Accounts Receivables history

USD · from the cash flow

Latest · FY2025
(8.79M) USD
Year-over-year change
-284.2%

Accounts Receivables vs competitors

How ADCT compares with its peers on the latest reported figures

  • ADCT's LTM Mar 2026 accounts receivables of $516.86K is the 7th largest of the 10 companies compared; the peer median is $0.
  • Its year-over-year change of +106.0% is the 3rd highest of 7, against a peer median of +45.3%.
  • Accounts receivables amounts to 0.7% of revenue for ADCT, versus a peer median of 9.4%.
ADCT Competitors Peer median
Accounts Receivables for ADCT and competitors
Company Period LTM YoY 3-year CAGR% of revenue
OMEROmeros CorporationLTM Mar 2026$29.33M -49.3%—296.5%
AUTLAutolus Therapeutics plcLTM Mar 2026$13.46M -6.1%—14.5%
LXRXLexicon Pharmaceuticals, Inc.LTM Mar 2026$9.33M +913.2%—13.4%
BCYCBicycle Therapeutics plcLTM Mar 2026$3.41M -86.4%—5.4%
QSIQuantum-Si incorporatedLTM Mar 2026$683K +174.7%—36.9%
LCTXLineage Cell Therapeutics, Inc.LTM Mar 2026$586K +96.6%—4.0%
ADCTADC Therapeutics S.A.LTM Mar 2026$516.86K +106.0%-41.0%0.7%
ALMSAlumis Inc. Common StockLTM Jun 2026$0 ——0.0%
FDMT4D Molecular Therapeutics, Inc.LTM Mar 2026$0 ——0.0%
NMRANeumora Therapeutics, Inc. Common StockLTM Mar 2026$0 ———
Peer median (excluding ADCT) $0+45.3%—9.4%

Competitors are the stored peer set for ADCT. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Cash Flow Statement

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Net Income(230.03M)(157.13M)(240.05M)(157.85M)(142.62M)
Depreciation & Amortization2.63M5.74M3.27M3.28M1.88M
Deferred Income Tax(26.05M)037.1M00
Stock-Based Compensation60.48M50.64M13.5M6.57M6.91M
Change in Working Capital(15.71M)(49.04M)44.27M3.83M(25.36M)
Accounts Receivables(30.22M)(42.75M)47.79M4.77M(8.79M)
Inventory(3.02M)(9.65M)(5.71M)(3.73M)(2.38M)
Accounts Payables6.8M310K3.17M2.46M(9.04M)
Other Working Capital10.73M3.37M(979K)321K(5.15M)
Other Non-Cash Items(24.7M)11.48M23.23M20.34M18.02M
Operating Cash Flow(233.38M)(138.31M)(118.69M)(123.84M)(141.17M)
Capital Expenditures(6.38M)(687K)(3.22M)(867K)(264K)
Acquisitions (Net)0000659K
Purchases of Investments00000
Sales of Investments00000
Other Investing Activities(3.24M)0000
Investing Cash Flow(6.67M)(687K)(3.22M)(867K)395K
Debt Repayment48.61M(2.71M)000
Common Stock Issued00060.51M152.46M
Common Stock Repurchased0(1.32M)000
Dividends Paid00000
Other Financing Activities218.78M3.13M73.88M36.55M(1.51M)
Financing Cash Flow267.39M(897K)73.88M97.05M150.95M
Effect of Forex Changes6K(208K)184K(83K)305K
Net Change in Cash27.35M(140.1M)(47.84M)(27.73M)10.47M
Free Cash Flow(239.75M)(139M)(121.9M)(124.7M)(141.44M)

ADC Therapeutics S.A.

NYSE:ADCT

Intrinsic Alpha fair value

Locked

Current Price

$1.37

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.